Solventum stock
SOLVNYSESolventum Corporation, HealthcareISIN US83444M1018
61Score 61 out of 100, Neutral
Price and trend
85 / 100
Price history
+20% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 4.1% below its 52-week high. Largest decline in 3 years: 40% (March 2024 to July 2024).
Chart figures for advanced users
- SMA 50$87.65
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$78.72
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$62.49
- The lowest closing price of the last twelve months.
- Resistance$92.44
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Solventum Corporation belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $15.06B, is number 12 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $8.33B (up 0.9% year on year) and earnings of $1.56B (up 224.8%).
- For fiscal 2026, analysts expect on average revenue of $8.24B (down 1.1%) and adjusted earnings per share of $7.15 (up 17.3%).
Show more
- MEQIRI Score 61 out of 100 (Neutral): rank 272 of 714 in Healthcare, median 53.
- The P/E is 97 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 12.1 (Medical (Instruments & Supplies) median 34.8). The P/E therefore does not count in the score.
- Our model puts fair value at $148.37, with the price 40% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 20.4% in fiscal 2025, Medical (Instruments & Supplies) median 5.4%.Profitability 52
Weaknesses
- High debtDebt 1.05 times equity (latest quarter), Medical (Instruments & Supplies) median 0.45.Stability 59
Its standout strengths are technical analysis and valuation, while growth holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 62 to 61.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- low growth grade (crashed less often in the backtest)
- price near its 52-week high
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $114.13 and expensive above $211.95 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $123.67, at 7.8% it would be $185.41.
Possible value trap: looks cheap, but weak growth.
Valuation metrics
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 2.8% on the twelve months before. Revenue has stayed largely stable since 2020.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 53%, operating 26%, net 19%. Last 12 months: net 2%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $1.45 (expected $1.34)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $7.15−0.1%
- Revenue
- $8.24B0.0%
- Earnings per share
- $7.330.0%
- Revenue
- $8.53B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −5.7%2026 EPS guidance raised to $7.10 to $7.20 (before: $6.40 to $6.60), operating margin to 22.2% to 22.7% and organic sales growth to 2.5% to 3%.
“We are tightening our organic sales growth range to the upper half of our initial 2% to 3% guidance range, raising our organic sales growth range to 2.5% to 3%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Wendell Amy McBridePurchase
10 Mar 2026, Board
- Shares
- 1,475
- Price
- $68.03
- Value
- $100,344
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Solventum
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- Sartorius Stedim BiotechDIM.PA $24.55B58
- Straumann HoldingSTMN.SW $20.49B78
- SartoriusSRT.DE $17.6B59
- ColoplastCOLO-B.CO $16.54B69
- Baxter InternationalBAX $13.63B47
- Cooper CompaniesCOO $11.97B61
- RepligenRGEN $11.03B51
- AvantorAVTR $10.66B53
ETFs that hold Solventum
Held by 30 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR HedgedXDEE | 0.20% | 0.30% | €14.88B |
| Invesco S&P 500 QVM UCITS ETFQVMP | 0.20% | 0.35% | €50.82M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.19% | 0.15% | €592.11M |
Show 5 more
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.19% | 0.15% | €3.27B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.18% | 0.30% | €944.34M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.17% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.13% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.09% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.